Loading...

Brilliant Violet 605™ anti-human CD69 Antibody

Pricing & Availability
Clone
FN50 (See other available formats)
Regulatory Status
RUO
Workshop
IV A91
Other Names
Very Early Activation Antigen (VEA), Activation inducer molecule (AIM)
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
FN50_BV605_CD69_Antibody_FC_071013
PMA+ ionomycin-stimulated (6 hours) human peripheral blood lymphocytes were stained with CD69 (clone FN50) Brilliant Violet 605™ (filled histogram) or mouse IgG1, κ Brilliant Violet 605™ isotype control (open histogram).
  • FN50_BV605_CD69_Antibody_FC_071013
    PMA+ ionomycin-stimulated (6 hours) human peripheral blood lymphocytes were stained with CD69 (clone FN50) Brilliant Violet 605™ (filled histogram) or mouse IgG1, κ Brilliant Violet 605™ isotype control (open histogram).
See Brilliant Violet 605™ spectral data
Cat # Size Price Quantity Check Availability Save
310937 25 tests $220
Check Availability


Need larger quantities of this item?
Request Bulk Quote
310938 100 tests $365
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD69 is a 27-33 kD type II transmembrane protein also known as activation inducer molecule (AIM), very early activation antigen (VEA), and MLR3. It is a member of the C-type lectin family, expressed as a disulfide-linked homodimer. Other members of this receptor family include NKG2, NKR-P1 CD94, and Ly49. CD69 is transiently expressed on activated leukocytes including T cells, thymocytes, B cells, NK cells, neutrophils, and eosinophils. CD69 is constitutively expressed by a subset of medullary mature thymocytes, platelets, mantle B cells, and certain CD4+ T cells in germinal centers of normal lymph nodes. CD69 is involved in early events of lymphocyte, monocyte, and platelet activation, and has a functional role in redirected lysis mediated by activated NK cells.

Product Details
Technical data sheet

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration
Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections2, immunofluorescence microscopy3, and spatial biology (IBEX)8,9.

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp WB, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Sakkas LI, et al. 1998. Clin. and Diag. Lab. Immunol. 5:430. (IHC)
  3. Kim JR, et al. 2005. BMC Immunol. 6:3. (IF)
  4. Verjans GM, et al. 2007. P. Natl. Acad. Sci. USA 104:3496.
  5. Lu H, et al. 2009. Toxicol Sci. 112:363. (FC) PubMed
  6. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
  7. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  8. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  9. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Sagebiel AF, et al. 2019. Nat Commun. 10:975. PubMed
  2. Hunter S, et al. 2018. J Hepatol. 69:654. PubMed
  3. Swadling L, et al. 2020. Cell Rep. 30:687. PubMed
  4. Hagan T, et al. 2020. Cell. 178(6):1313-1328.e13.. PubMed
  5. Singh S, et al. 2020. Cell Reports Medicine. 1(3):100033. PubMed
  6. Tsai C, et al. 2015. J Immunol. 194:3890. PubMed
  7. Roberts E, et al. 2016. PLoS One. 11:e0168488. PubMed
  8. Zhang B, et al. 2020. Cell Chemical Biology. 28(1):60-69.e7. PubMed
  9. Richert-Spuhler LE, et al. 2021. Cell Reports Medicine. 2(6):100322. PubMed
  10. Cheng Y, et al. 2021. Immunity. 54(8):1825-1840.e7. PubMed
  11. Zabaleta N, et al. 2021. Cell Host Microbe. :. PubMed
  12. Duhen R, et al. 2021. Nat Commun. 12:1047. PubMed
  13. Apostolidis SA, et al. 2021. Nat Med. 27:1990. PubMed
  14. Muliaditan T, et al. 2021. Cell Rep Med. 2:100457. PubMed
  15. Lederer K, et al. 2022. Cell. . PubMed
  16. Haruna M, et al. 2020. Biol Pharm Bull. 43:399. PubMed
  17. Rajamanickam V, et al. 2021. Cancer Immunol Res. 9:602. PubMed
  18. Mysore V, et al. 2021. Med (N Y). 2:1050. PubMed
  19. Painter MM, et al. 2021. Immunity. 54:2133. PubMed
  20. Wilson TL, et al. 2022. Cancer Discov. 12:2098. PubMed
  21. Ackerley CG, et al. 2022. Front Immunol. 13:972170. PubMed
  22. Li Y, et al. 2022. J Med Virol. 94:3998. PubMed
  23. Chen Y, et al. 2022. Sci Immunol. 7:eabp8328. PubMed
  24. Eschweiler S 2023. Cell Reports. 42(2):112040. PubMed
RRID
AB_2562306 (BioLegend Cat. No. 310937)
AB_2562307 (BioLegend Cat. No. 310938)

Antigen Details

Structure
C-type lectin, type II glycoprotein, 28/32 kD
Distribution

Activated T cells, B cells, NK cells, granulocytes, thymocytes, platelets, Langerhans cells

Function
Lymphocyte, monocyte, and platelet activation, NK cell killing
Cell Type
B cells, Granulocytes, Langerhans cells, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Testi R, et al. 1994. Immunol. Today 15:479.

Gene ID
969 View all products for this Gene ID
UniProt
View information about CD69 on UniProt.org
Go To Top Version: 1    Revision Date: 07/19/2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account